Cancers 2022, 14, 1619. https://doi.org/10.3390/cancers14071619

Targeted Dual-Modal PET/SPECT-NIR Imaging: From Building Blocks and Construction Strategies to Applications

Syed Muhammad Usama 1,†, Sierra C. Marker 1,†, Servando Hernandez Vargas 2,†, Solmaz AghaAmiri 2, Sukhen C. Ghosh 2, Naruhioko Ikoma 3, Hop S. Tran Cao 3, Martin J. Schnermann 1,* and Ali Azhdarinia 2,*

1 Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; syed.usama@nih.gov (S.M.U.); sierra.marker@nih.gov (S.C.M.)
2 The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; servando.hernandezvargas@uth.tmc.edu (S.H.V.); solmaz.aghaamiri@uth.tmc.edu (S.A.); sukhen.ghosh@uth.tmc.edu (S.C.G.)
3 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; nikoma@mdanderson.org (N.I.); hstran@mdanderson.org (H.S.T.C.)

* Correspondence: martin.schnermann@nih.gov (M.J.S.); ali.azhdarinia@uth.tmc.edu (A.A.)
† These authors contributed equally to this work.

Simple Summary: Targeted dual-modal imaging agents for whole body PET/SPECT imaging and fluorescence-guided surgery (FGS) have significant potential to improve surgical workflow. Here we present an overview of key design considerations and fluorescent building blocks, along with potential future directions in this exciting field.

Abstract: Molecular imaging is an emerging non-invasive method to qualitatively and quantitatively visualize and characterize biological processes. Among the imaging modalities, PET/SPECT and near-infrared (NIR) imaging provide synergistic properties that result in deep tissue penetration and up to cell-level resolution. Dual-modal PET/SPECT-NIR agents are commonly combined with a targeting ligand (e.g., antibody or small molecule) to engage biomolecules overexpressed in cancer, thereby enabling selective multimodal visualization of primary and metastatic tumors. The use of such agents for (i) preoperative patient selection and surgical planning and (ii) intraoperative FGS could improve surgical workflow and patient outcomes. However, the development of targeted dual-modal agents is a chemical challenge and a topic of ongoing research. In this review, we define key design considerations of targeted dual-modal imaging from a topological perspective, list targeted dual-modal probes disclosed in the last decade, review recent progress in the field of NIR fluorescent probe development, and highlight future directions in this rapidly developing field.

Keywords: dual-modal imaging; fluorescence-guided surgery; PET/SPECT imaging; heptamethine

1. Introduction

Nuclear medicine is an imaging specialty that uses radiolabeled contrast agents (i.e., radiotracers) to non-invasively assess biological processes. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are nuclear imaging modalities that generate three-dimensional images of radiotracer distribution, and are widely used in oncology, cardiology, and neurology to detect and monitor disease progression [1,2]. In cancer, diagnostic radiotracers typically comprise a targeting moiety, such as a small molecule, peptide, or antibody that is preferentially taken up by tumors, and a radionuclide that emits positrons or gamma rays for PET or SPECT imaging, respectively. The tumor-specific contrast generated by such agents has motivated imaging applications outside of nuclear medicine whose success is growing. Most notably, fluoroscence-labeled agents now have over a decade of clinically proven utility in the emerging field of...
fluorescence-guided surgery (FGS) [3–11]. FGS is an intraoperative optical imaging modality that visually augments the surgical field to improve the identification of small tumors, multifocal diseases, and surgical margins. The display of real-time images in the operating room would address the limitations of existing intraoperative imaging techniques and has the potential to enable more complete tumor resections with minimal damage to normal structures (i.e., healthy tissue, nerves, and vasculature).

A conventional tumor-specific FGS agent combines a targeting component and a dye that preferably emits fluorescence in the near-infrared (NIR) spectral range (wavelengths > 700 nm), where tissue autofluorescence is low and increased depth of detection is possible [12]. Given the comparable detection sensitivities of optical and nuclear imaging (i.e., high fM–pM), there have also been extensive efforts to synthesize dual-modal FGS agents that contain both fluorescent and radioactive labels. Such agent design would broaden the imaging utility of a single agent for preoperative and intraoperative purposes (Figure 1a), while affording tools to overcome limitations of the individual modalities. For instance, fluorescence imaging is inherently semi-quantitative due to the physics of the low energy photons (~1.5 eV) involved, and thus, quantitative cross-validation of fluorescence readouts is possible at the whole body scale via PET or SPECT imaging, and at the organ scale by measuring drug distribution by gamma counting [13]. Houston and coworkers introduced the first dual-modal NIR agent using an $\alpha_v\beta_3$-targeted peptide labeled with $^{111}$In via the chelating agent diethylenetriaminepentaacetic acid (DTPA) for gamma scintigraphy and the cyanine dye, IR-800CW, for optical imaging of melanoma in mice [14]. A major finding from their work was the ability to obtain congruent nuclear and optical signals following administration of a trace dose. This feasibility study showed for the first time that NIR and nuclear imaging can synergize and provided a foundation for developments focused on (i) chemical design strategies to simplify bioconjugation and (ii) integration of a broad range of radionuclides and dyes [15–17].

Several design strategies have been used to develop dual-labeled agents for nuclear/NIR imaging (detailed in Section 2). Generally, imaging scientists have combined clinically used radiometals (i.e., $^{68}$Ga, $^{111}$In, $^{89}$Zr) and their associated chelators, such as DTPA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and desferrioxamine (DFO), with commercially available NIR dyes, such as IR-800CW, through a variety of linker technologies to biomolecules. Notably, antibody- and peptide-based approaches have pioneered the recent translation of this multimodal imaging approach and demonstrated safety and feasibility [18]. For example, sequential labeling using a validated and readily available monoclonal antibody (mAb) was implemented in the clinic with $^{111}$In-DOTA-girentuximab-IR-800CW for clear cell renal cell carcinoma (ccRCC, Figure 1b) resection [19]. Conversely, the use of low molecular weight agents (i.e., small molecules and peptides) typically requires more complex chemical linker strategies to preserve binding and pharmacokinetic properties. To address this challenge, $^{68}$Ga-NOTA-BBN-IR-800CW, which targets the gastrin-releasing peptide receptor (GRPR) using a 14 amino acid sequence peptide, was derived from a PET radiotracer and applied for glioblastoma (Figure 1c) [20]. Both of these studies illustrate the potential utility of the dual-modal approach to streamline the clinical workflow (pre- to intraoperative imaging) and mediate superior outcomes (increase surgical sensitivity).

The clinical utility of tumor-specific FGS is increasingly evident and has benefited from advances in NIR dye development. OTL38 (pafolacianine, CYTALUX™) is a NIR-emitting folate-receptor targeting agent that recently gained FDA approval after demonstrating increased tumor detection in 27% of patients with ovarian cancer in a phase 3 trial (NCT03180307). A critical step in the translation of this agent was the implementation of the customized NIR dye S0456, which retained the brightness of commercially available cyanine dyes and avoided the prominent formation of side-products [21]. Several recent reviews have comprehensively described developments in chelator chemistry, and the preclinical and clinical development of dual-modal agents [18,22–29]. Here, we highlight recent advances in the development of dual-modal imaging agents bearing NIR and
short-wavelength infrared (SWIR)/NIR-II (absorbance maxima > 700 nm) fluorophores. Furthermore, we focus on the fluorophore component due to extensive recent progress in this area and the potential for these agents to drive future developments. We hope that presenting these studies stimulates efforts to develop the next-generation of dual-modal PET/SPECT-NIR imaging agents with superior performance for clinical use.

2. Design of Dual-Modal Imaging Probes

From a topological perspective, targeted bifunctional probes may be divided into four broad categories (Figure 2). For class I, the fluorophore acts as the bifunctional component connecting the targeting ligand and radionuclide. In class II, a chelator or metal-binding ligand connects the other two functionalities. In class III, the targeting ligand is the linking element. Lastly, class IV probes are connected by a trifunctional linker. To prepare these multi-component agents, a variety of bioorthogonal reactions are used in combination with conventional amide-bond forming reactions. These methods have been reviewed extensively elsewhere [30–32]. In this section, we include recent examples of dual-modal probe construction.
weight radiotracers in the clinic. We utilized copper-free click chemistry to attach IR-800CW to the MMC-conjugated somatostatin analog MMC-TOC (TOC = Tyr<sup>3</sup>-octreotide) [38]. Radiolabeling with <sup>64</sup>Cu allowed whole-body PET imaging in mice bearing somatostatin

Figure 2. Classification of targeted-bifunctional (chelator/radionuclide and fluorophore) probes into four generic classes based on connectivity logic: class I—bifunctional fluorophores, class II—bifunctional chelators, class III—bifunctional ligands, and class IV—trifunctional linker connecting chelators, fluorophores, and targeting ligands.

Class I strategies require a bifunctional fluorescent probe. One such example is the bifunctional cyanine fluorophore, which uses clickable handles to attach a cRGD (cyclic arginine-glycine-aspartic acid)-targeting peptide and <sup>18</sup>F as the PET-emitting isotope via a one-pot synthetic method (Figure 2) [33]. The <sup>18</sup>F–<sup>19</sup>F radiolabeling is performed on a zwitterionic organotrifluoroborate using isotope exchange (IEX) under acidic conditions. The labeling reaction results in moderate radiochemical yields (~20–25%) following purification using a C18 cartridge [34]. Tumor-to-muscle ratios of 3 using both nuclear- and fluorescence-based imaging in mice bearing glioma xenografts indicated the suitability of the NIR scaffold for dual-modal probe development. While not involving a NIR fluorophore, work by Ting and coworkers developed a related prostate-specific membrane antigen (PSMA) inhibitor, the ACUPA-Cy3-BF<sub>3</sub> probe, which is currently being investigated in clinical studies for the treatment of prostate cancer [35–37].

Just as the fluorophore can be bifunctional, so too can the chelator element in class II strategies (Figure 2). A notable approach in this class was reported by our group, which was enabled by developing a DOTA-based analog (referred to as a multimodality chelator, MMC) with a customized pendant arm for facile bioconjugation. Our chemical design strategy maximizes the distance between the dye and targeting ligand (i.e., reduces steric interactions between these components) while maintaining the chemical footprint of low molecular weight radiotracers in the clinic. We utilized copper-free click chemistry to attach IR-800CW to the MMC-conjugated somatostatin analog MMC-TOC [39]. Radiolabeling with <sup>64</sup>Cu allowed whole-body PET imaging in mice bearing somatostatin
receptor subtype 2 (SSTR2) positive AR42J tumors. Ex vivo analysis of tumors and normal organs using gamma counting and optical imaging illustrated consistent signal localization. In subsequent studies, we modified a pendant arm of the MMC to enable stable chelation of $^{68}$Ga and $^{67}$Ga, which permitted PET imaging and delayed (up to 48 h) biodistribution analysis, respectively [39,40].

The majority of dual-modal conjugates fall into class III, where the targeting agent serves as the bifunctional group (Figure 2). These agents include dual-labeled mAbs such as $^{111}$In-DOTA-girentuximab-IR-800CW, as described above in Figure 1b. Using a similar topology, a pre-targeting approach was reported for detecting prostate cancer by appending DyLight 800 and DOTA through a dual-labeled diHSG (histamine–succinyl–glycine) peptide (RDC018) [41]. Mice bearing trophoblast cell surface antigen 2 (TROP-2)-expressing PC-3 prostate tumors were injected with anti-TROP-2 x anti-HSG bispecific antibody (TF12), followed by a second injection with the $^{111}$In-labeled DOTA-DyLight 800 conjugate. Pre-targeting led to selective uptake of RDC018 in prostate tumors for SPECT and optical imaging, with high tumor-to-background ratios (TBRs) as early as 2 h post-injection. The conjugate showed good tumor uptake in both soft tissue and bone metastases, but did exhibit high kidney accumulation, a typical issue with small molecule and peptide conjugates.

Lastly, class IV utilizes careful linker design to attach the three components (Figure 2). As described above (Figure 1c), a clinically applied class IV dual-conjugate was developed by attaching NOTA (for $^{68}$Ga labeling) and bombesin via a bifunctional linker to IR-800CW [20]. This study illustrated the benefits of a dual-modal agent in a clinical setting. Importantly, this method allowed for complete resection of these tumors from six of the eight patients, with the major limitation being detection of deep-seated tumors. In a separate preclinical study, ZW800-1 was linked to the chelator Dfo for $^{89}$Zr radiolabeling and the targeting agent cRGD ($\alpha_\text{V}\beta_3$ integrin) [42]. Sibinga Mulder and coworkers showed that the conjugate could detect tumors through PET imaging. The conjugate also showed high signal-to-background ratios (SBRs) by optical imaging at early time points due to the rapid renal clearance of the conjugate.

In Tables 1 and 2, we provide a systematic overview of all studies reported between 2011 and 2022 of PET/SPECT-NIR fluorophore (absorbance maxima > 700 nm) dual-modal imaging agents. One clear trend is that mAb-targeting agents generally use class III “double-labeling” strategies. One emerging area is the development of homogenous protein labeling methods, which has been investigated for both pretargeting and direct dual labeling [43–45]. Going forward, there is significant potential to apply class I, II, and IV strategies to antibody and protein targeting agents, which may also benefit from homogenous bioconjugation approaches.

### Table 1. Fluorophore–radionuclide small-molecule conjugates reported in 2011–2022.

| Class | Dye | Radionuclide | Chelator | Targeting Group | Receptor | Reference |
|-------|-----|--------------|---------|-----------------|----------|-----------|
| IV    | IR-800CW | $^{68}$Ga | NOTA | Bombesin | GRPR | [20] |
| IV    | ICG Analog | $^{111}$In | DTPA | cRGD | $\alpha_\text{V}\beta_3$ | [46] |
| III   | DyLight 800 | $^{111}$In | DOTA | diHSG peptide | TF12 | [41] |
| N/A   | Sulfo-Cyanine7 and IR-800CW | $^{68}$Ga | FSC | N/A | N/A | [47] |
| N/A   | ICG | $^{68}$Ga | NOTA | N/A | N/A | [48] |
| N/A   | MHI-148 | $^{64}$Cu | DOTA | N/A | N/A | [49] |
| N/A   | MHI-148 | $^{68}$Ga | DOTA | N/A | N/A | [50,51] |
| N/A   | MHI-148 | $^{99m}$Tc | HYNIC | N/A | N/A | [52] |
| N/A   | MHI-148 | $^{64}$Cu | DOTA | N/A | N/A | [53] |
| III   | ZW800-1 | $^{89}$Zr | Dfo | cRGD | $\alpha_\text{V}\beta_3$ | [42] |
| II    | IR-800CW | $^{64}$Cu | MMC | Octreotide | Somatostatin | [38] |
| II    | IR-800CW | $^{67/68}$Ga | MMC | Octreotide | Somatostatin | [39,40] |
| IV    | IR-800CW and DyLight800 | $^{68}$Ga | HBED-CC | Glu-urea-Lys(Ahx) | PSMA | [54] |
Table 1. Cont.

| Class | Dye                        | Radionuclide | Chelator | Targeting Group | Receptor       | Reference |
|-------|----------------------------|--------------|----------|-----------------|----------------|-----------|
| III   | SWIR dye 68Ga              | DOTA         | cRGD     | αvβ3            | [55]           |
| II    | Sulfo-Cyanine7 68Ga         | FSC          | cRGD, MG11 | αvβ3, CCK2R     | [56]           |
| IV    | IR-800CW 111In, 99mTc 64Cu | DOTA         | Glu-urea-Lys analogs | PSMA          | [57]           |

N/A = not applicable.

Table 2. Fluorophore-radionuclide antibody conjugates reported in 2011–2022.

| Class | Dye                        | Radionuclide | Chelator | Targeting Group | Receptor       | Reference |
|-------|----------------------------|--------------|----------|-----------------|----------------|-----------|
| IV    | ZW800-1(DTPA-Lys(ZW800)-Cys-NHS)structure not revealed | 111In | DTPA | ATN-658 | uPAR | [58,59] |
| III or IV | IR-800CW 89Zr            | Dfo          | 5B1      | CA19.9          | [43]           |
| III   | IR-800CW 111In            | DOTA         | Farletuzumab | FRα            | [60]           |
| III   | IR-800CW 64Cu             | DOTA         | MAB9601  | EpCam           | [61]           |
| III   | IR-800CW 111In            | DTPA         | BIWA     | CD44v6          | [62]           |
| III   | IR-800CW 89Zr             | Dfo          | TRC105   | CD105           | [63]           |
| III   | IR-800CW 64Cu             | NOTA         | TRC105   | CD105           | [64,65]        |
| III   | IR-800CW 89Zr             | Dfo          | TRC105, Cetuximab CD105, EGFR | [65]           |
| III   | IR-800CW 89Zr             | Dfo          | Pertuzumab | HER2           | [67]           |
| III   | IR-800CW 89Zr             | Dfo          | Cetuximab | EGFR           | [68]           |
| III ZW800-1 | 89Zr                  | Dfo          | YY146    | CD146           | [69]           |
| III   | IR-800CW 64Cu             | NOTA         | Bevacizumab | VEGF           | [70]           |
| III   | IR-800CW 111In            | DTPA, DOTA   | Girentuximab CA-IX | CEA           | [71,72]        |
| III   | IR-800CW 111In            | DTPA         | Labetuzumab | CEA           | [73]           |
| III   | IR-800CW 111In            | DTPA         | D2B      | PSMA            | [74]           |
| III   | IR-800CW 111In            | DTPA         | MN-14    | CEA             | [75]           |
| III   | IR-800CW 111In            | DTPA         | Girentuximab, Cetuximab, CEA, MN-14, CEACAM5, CA-IX, EGFR | [76]           |
| III   | IR-800CW 64Cu             | SarAr Analog | huA33    | A33             | [44]           |
| III   | IR-800CW 64Cu             | DOTA         | 15D3     | Pgp             | [77]           |
| III   | IR-800CW 64Cu             | NOTA         | CD105    | TGF-β           | [78]           |
| III   | XB1034 68Ga               | NETA         | Cetuximab | EGFR           | [79]           |
| IV    | IR-800CW 89Zr             | Dfo          | Trastuzumab | HER2           | [45]           |
| III   | IR-800CW 124I             | N/A          | A2cDb    | PSCA            | [80]           |
| I Aza-BODIPY | 111In              | DOTA         | Trastuzumab | HER2           | [81]           |

3. Recent Developments in NIR and SWIR Fluorophores

Of the two key components of these dual-modal agents, the fluorophore and radionuclide, the latter has been reviewed extensively, including in this volume [82–84]. Consequently, here we focus on the fluorophore component. Fluorescence-based methods enable many cellular and in vitro biomedical experiments. In the last two decades, optical methods have been employed for in vivo applications, including in various preclinical contexts and FGS applications. In vivo imaging puts demands on these fluorescent probes that in vitro cellular imaging does not. There are significant advantages to extending the excitation and emission wavelengths into the NIR region (700–950 nm) and short-wavelength IR region (NIR-II/SWIR, 950–1700 nm) [85,86]. These advantages include enhanced penetration due to reduced absorption and scattering by tissues and blood, and reduced background signal due to lower tissue autofluorescence [87,88]. Additionally, these wavelengths reduce phototoxicity, which allows higher irradiation intensities to be used [89–91]. However, the chemistry of NIR probes is a significant challenge. In particular, the requirement of an extended π-system introduces a highly hydrophobic element into the chemical structure.
This component must be accommodated through the addition of polar functional groups to improve water solubility and reduce probe aggregation.

3.1. NIR Fluorophores

Heptamethine indocyanines are privileged scaffolds for optical imaging in the NIR region [92,93]. These molecules exhibit absorbance/emission maxima of around 800 nm, exceptionally high extinction coefficients ($\epsilon \approx 150,000$–$300,000$ M$^{-1}$ cm$^{-1}$), and useful quantum yields ($\Phi_F$). The potential of these probes was first realized with indocyanine green (ICG), which was developed by Kodak Research Laboratories (Figure 3a). ICG was FDA approved in 1959, and was originally used to test hepatic function [94]. Due to its regulatory approval, ICG has been used in a variety of settings. In particular, the ability of ICG to target a multitude of tumor types through passive targeting mechanisms, including various liver cancers, has led to its broad use by groups around the world [95–99]. While useful for certain imaging applications, ICG is not suitable for active targeting. A critical advance in this area was the development of the “Cy-dyes” by Waggoner and coworkers, which involved sulfonating the parent indocyanine indolenine rings (GE-Cy7) [100,101]. Complementing these efforts, Strekowsk and coworkers discovered that readily accessible 4'-chloro ring-modified cyanines can be converted to C4'-phenol-substituted cyanines (Figure 3a) [102]. Subsequent efforts using these modification concepts led to the broadly used commercial probes IR-800CW and DyLight 800. In particular, IR-800CW has been employed in numerous clinical trials [103–105]. The folate-receptor targeting OTL38, which was recently FDA approved for identifying ovarian cancer lesions, also uses this ring modification strategy [5,21,106–108].

Several studies have shown that persulfonated anionic probes reduce the in vivo targeting of the parent agent [109–111]. Moreover, it has become clear that highly charged but overall net neutral (or nearly neutral) probes offer significant benefits [109,112]. The zwitterionic fluorophore ZW800-1 was developed by the combined efforts of Choi and Henary, and Frangioni and coworkers [113,114]. While their efforts improved the properties of peptide conjugates, these probes were not optimized for mAb labeling. Through iterative efforts, our group examined a series of C4'-O-alkyl derivatives [115–118]. These efforts led to FNIR-Tag, a sulfonated, pegylated probe that contains a quaternary amine at the C4' position (Figure 3a). FNIR-Tag exhibits excellent photophysical properties in a range of contexts, including on proteins, on fluorescence resonance energy transfer (FRET)-pairs, and on virus-like particles (VLPs) [119,120]. Additionally, efforts by Smith and coworkers led to the discovery of s775z (Figure 3a), a zwitterionic, pegylated probe, which was developed by introducing 2,5-disubstituted aryl derivatives at the C4' position. This probe decreases fluorophore aggregation and improves the in vivo properties of mAb conjugates [121].

In addition to progress with actively targeted probes, there have been developments in probes with intrinsic tumor targeting properties. The C4'-chloro-containing cyanine named MHI-148 (Figure 3a) specifically localizes and persists for days in several preclinical solid tumor models (i.e., kidney, lung, brain, breast, and prostate) [122–124]. This targeting property has been attributed to organic anion transporting polypeptide (OATP) transporters [125–128]. A more hydrophilic version, with a quaternary amine in the cyclohexyl core, was reported by Burgess and coworkers (QuatCy) [129]. This compound maintains efficient tumor targeting in a mouse model of pancreatic cancer (NIT-91). It was also shown to covalently interact with serum proteins—a potential mechanism for other tumor-targeting C4'-chloro-substituted cyanines.
Figure 3. Overview of recent developments of fluorophores with absorbance/emission maxima in the (a) near-infrared and (b) short-wavelength IR regions. Blue, red, and green colors indicate cationic, anionic, and conjugable functional groups, respectively.

3.2. SWIR/NIR-II Fluorophores

Advances in instrumentation, particularly the sensitivity of InGaAs detectors, have made it possible to image in the SWIR region [130]. These wavelengths have significant potential to provide improved resolution for in vivo imaging. While efforts have been applied to generate quantum dots, carbon nanotubes, earth-doped nanoparticles, and other nanomaterial/polymer materials, active-targeting approaches with these agents come with significant challenges [131–134]. Early efforts to create organic fluorophores in this wavelength range mainly focused on exploiting benzobis(thiadiazole) (BBT, donor–acceptor–donor (DAD)) moieties [135]. However, the early versions of these probes were prone to aggregation and fluorescence quenching. To overcome this challenge, the Dai group introduced an alkoxy shielding unit and carefully optimized the chromophore, which significantly improved the properties of these probes in aqueous solutions (IR-BGP6, Figure 3b) [136,137].

Cyanines have significant potential for use in SWIR imaging. Studies by Bruns and coworkers revealed that ICG, when excited at its $\lambda_{\text{max}}$, exhibits an SWIR signal at a wavelength of 1150 or 1300 nm [138]. This approach has been validated by several groups, and even applied in clinical settings. Building on these observations, various studies have sought to capitalize on the potential of cyanine derivatives in this setting. Lan and coworkers employed a thiopyrylium moiety on the monomethine to extend the photophysical properties into the SWIR region, which was targeted with the FDA-approved mAb cetuximab. Other promising efforts in this area include studies that employ flavylium
heterocycles on the heptamethine cyanine scaffold. These probes have been employed for various untargeted applications and have the potential to be extended to targeted imaging [139–141]. We recently demonstrated that dichloro-substituted nonamethine cyanine derivatives could be modified with either catechols or through direct aryl fusion to generate FNIR-866 and FNIR-1072, respectively (Figure 3b). These probes can be used as mAb-targeted agents for multicolor surgical applications [142]. Overall, the rapid progress in the field of long-wavelength probe chemistry is opening up a range of exciting possibilities.

4. Future Directions of Dual-Modal Imaging

Dual-modal imaging is an emerging field that can bridge gaps in nuclear medicine and surgical oncology. There are a range of exciting unexplored directions in the design and application of these dual-modal agents. Below we focus on potential research utilizing novel fluorophore elements and methods for developing new dual-modal probes, and the applications of dual-modal imaging agents to therapeutic development.

4.1. Probe Development

In addition to clinical applications, dual labeling also plays an important role in characterizing the performance of FGS agents in the preclinical setting, both in vitro and in vivo, as shown in the characterization of our dual-labeled somatostatin analog [38]. For instance, in parallel with conventional fluorescence-based assays, such as flow cytometry and microscopy, dual labeling with radiometals ($^{64}$Cu, $^{67}$Ga, $^{68}$Ga) allowed quantitative assessments of cell binding with traditional radioligand studies [38–40]. These experiments included a clinically validated radiotracer ($^{68}$Ga-DOTA-TOC) as a performance benchmark and provided valuable cross-validation of fluorescence findings. Furthermore, the quantitative comparison of $^{68}$Ga-MMC(IR800)-TOC to $^{68}$Ga-DOTA-TOC in vivo strengthened our understanding of off-target uptake (i.e., blood half-life) and provides a rationale for optimization with some of the dyes discussed herein. Conversely, fluorescence imaging of a dual-labeled tumor targeting agent has been used to identify the sub-cellular distributions of radiopharmaceuticals [143]. Dual-modal imaging can also be used in translational studies by ex vivo staining of human tumor tissues and subsequent fluorescent imaging and autoradiography of the tissue section, as described by Rijpkema and coworkers [144].

4.2. Activatable Bifunctional Probes

Most targeted bifunctional probes utilize an “always-on” fluorophore that emits fluorescence irrespective of binding to the target protein. These fluorophores have the disadvantage of needing long in vivo clearance times before attaining good SBRs, a problem that is compounded for large molecules such as antibody conjugates [145]. This issue could be overcome by using activatable or “turn-on” fluorophores, which stay in their respective off states, or non-fluorescent forms, until activated by the desired enzymes or triggers [146,147]. Such activation methods can accelerate the ability to attain meaningful image contrast [148].

One method of probe activation uses a FRET-quenched bifunctional probe targeting MMP-14, an enzyme overexpressed in glioblastoma (Figure 4a) [149]. The probe design consists of an MMP-14 substrate peptide and an MMP-14 binding peptide connected through a linker. The peptides were attached to the quencher QC-1 (LiCor Bioscience®, Lincoln, NE, USA), the fluorophore IR-800CW, and the chelator NOTA for PET labeling. Upon enzymatic cleavage of the quencher from IR-800CW, which is achieved in the protease-rich tumor milieu, fluorescence turn-on is observed. In vivo, the authors observed a strong correlation between the PET and NIR signal. The fluorescence signal from the probe exhibited a high TBR of 8–11 4 h post-injection that was in accordance with PET imaging using $^{68}$Ga and $^{64}$Cu.
We have shown that these probes can be conjugated to antibodies and applied to phototherapy. Among these photosensitizers, IR700-DX, a silicon-phthalocyanine-based dye, has shown promising therapeutic properties upon conjugation to antibodies, such as activatable or non-FRET-based turn-on strategies in the NIR range. Fluorogenic heptamethine cyanine fluorophores were generated by forming norcyanine carbamates (CyBam) [150,151]. This strategy avoids the chemical complexity of a quencher group. We have shown that these probes can be conjugated to antibodies and applied to the characterization of antibody-drug conjugate linker chemistry in vivo (Figure 4b). This approach may allow conventional mAbs to achieve high-contrast optical signals shortly after systemic administration, though further optimization of the probe component is required to enable dual-modal imaging.

4.3. Therapeutic Approaches

In addition to implementing new fluorophore design strategies into dual-modal agents, therapeutic translation is another possibility. The transformation of molecular-targeted tumor imaging strategies into therapeutic modalities is a long-standing goal. One method that can be used to achieve this goal is phototherapy. Phototherapy consists of photodynamic and photothermal approaches and seeks to eradicate tumors in an irradiated region [152,153]. The photosensitizer Photofrin and 5-aminolevulinic acid (5-ALA), a biosynthetic precursor of protoporphyrin IX, are two phototherapeutic agents approved by the FDA for melanoma and glioblastoma multiforme, respectively. Several other probes based on cyanine scaffolds and other fluorophores are in preclinical and clinical trials for phototherapy [152,154]. Among these photosensitizers, IR700-DX, a silicon-phthalocyanine-based dye, has shown promising therapeutic properties upon conjugation to antibodies [155–158] or to PSMA-targeting ligands [159,160] and has recently advanced in a range of clinical studies [161,162]. For dual-modal labeling, Rijpkema and coworkers developed a multi-modal PSMA-targeting agent by labeling an anti-PSMA mAb (D2B) with IR700-DX and 111In (Figure 4c) [155]. They performed preoperative imaging studies with SPECT/CT and NIR imaging and showed clear tumor visualization with both modalities in the subcu-
taneous PSMA+ xenografts, indicating applicability of the conjugate for surgical guidance. In addition, photodynamic therapy of tumor-bearing mice after injection of the agent and subsequent treatment with 100 J/cm² of NIR light resulted in a significant delay in tumor growth and longer survival rates with median survival at 73 and 16 days for the treated group and control group, respectively [159,160]. These studies demonstrate the potential of IR700-DX for applications in whole-body tumor delineation, FGS-based tumor resection, and tumor ablation through phototherapy.

5. Conclusions

Here we provided an overview of the chemical design features of dual-modal PET/SPECT-NIR agents, with specific focus on the fluorophore components. Key aspects of these approaches include the design of the conjugation strategy (i.e., class I–IV) and selection of the individual components, particularly dyes, which can affect targeting and pharmacokinetic properties, and thus, image contrast. The relative benefits of each of these strategies and component selection remain to be fully assessed and likely will depend on the context in which they are applied. Given the existing role of nuclear imaging in pre-operative assessment and surgical planning ahead of FGS procedures, novel fluorophores could be used in innovative pairings with various imaging radionuclides. Furthermore, it would be of great utility to use the same agent for (i) preoperative patient selection and surgical planning with PET or SPECT and (ii) intraoperative FGS, thereby reducing drug development costs while affording signal congruence (i.e., arising from the same origin) regardless of detection modality. Such capabilities would address the lack of biomarker (i.e., folate receptor) specificity associated with “standard” metabolic imaging findings from 18F-fluorodeoxyglucose (FDG)–PET and increase the accuracy of patient selection and significance of preoperative planning. Continued multidisciplinary efforts are thus essential for defining the roles of these emerging chemical strategies and broadening the impact of intraoperative imaging in cancer.

Author Contributions: Conceptualization, S.M.U., S.C.M., S.H.V., M.J.S. and A.A.; writing—original draft preparation, S.M.U., S.C.M., S.H.V., S.A., S.C.G., N.I., H.S.T.C., M.J.S. and A.A.; writing—review and editing, S.M.U., S.C.M., S.H.V., M.J.S. and A.A.; supervision, M.J.S. and A.A.; funding acquisition, M.J.S. and A.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Cancer Prevention and Research Institute of Texas (RP180812); the John S. Dunn Research Scholar Fund; and the Intramural Research Program of the National Institutes of Health, National Cancer Institute (NCI), Center for Cancer Research (BC011506 and BC011564).

Conflicts of Interest: The authors declare the following competing financial interest(s): a patent describing these probes has been submitted.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| AMBF3        | ammonium methyltrifluoroborate |
| CT           | computerized tomography |
| Dfo          | desferrioxamine B |
| DOTA         | 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid |
| FSC          | Fusarinine C |
| MMC          | multimodality chelator |
| HYNIC        | 6-hydrazinonicotinic acid |
| DTPA         | diethyleneetriaminopentaacetic acid |
| EPR          | enhanced permeability and retention |
| FDG          | 2-deoxy-2-fluoro-D-glucose |
| GBM          | glioblastoma multiforme |
| HBED-CC      | N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]-ethylenediamine-N,N′-diacetic acid |
| MRI          | magnetic resonance imaging |
NIR near-infrared
NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid
QC-1 fluorophore quencher
PDT photodynamic therapy
PEG polyethylene glycol
PET positron emission tomography
RGD Arg-Gly-Asp
SPECT single-photon computerized tomography
ACUPA (N-[[([1S]-5-Amino-1-carboxypentyl]amino)carbonyl]-L-glutamic acid
TOC Tyr3-octreotide
IEX isotope exchange
CCK2R cholecystokinin-2 receptor
αVβ3 alpha V and integrin beta 3
MG11 minigastrin analogue
BBN bombesin
HSG histamine–succiynyl–glycine
PSMA prostate specific membrane antigen
5-Ala 5-aminolevulinic acid
FRET fluorescence resonance energy transfer
SarAr hexaazamacrobicyclic cage ligand 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane-1,8-diamine
NETA 2-((1-[1,4,7-bis(carboxymethyl)-1,4,7-triazanonan-1-yl]-7-(4-nitrophenyl)heptan-2-yl)(carboxy-methyl)amino)acetic acid
SSTR2 somatostatin receptor subtype 2
TF-12 anti-TROP-2 x anti-HSG bispecific antibody
EGFR epidermal growth factor receptor
MMP-14 matrix metalloproteinases-14
GRPR gastrin-releasing peptide receptor
FGS fluorescence-guided surgery
SWIR short-wavelength infrared
ccRCC clear cell renal cell carcinoma
VLP virus-like particles
OATP organic anion transporting polypeptide
DAD donor-acceptor-donor
BBT benzobis(thiadiazole)
CA-IX carbonic anhydrase IX
cRGD cyclic arginine-glycine-aspartic acid
diHSG histamine–succiynyl–glycine
uPAR urokinase plasminogen activator surface receptor
CA19.9 pancreatic cancer biomarker
EpCAM epithelial cell adhesion molecule
HER2 human epidermal growth factor 2
EGFR epidermal growth factor receptor
mAb monoclonal antibody
CD146 melanoma cell adhesion molecule
VEGF vascular endothelial growth factor
CEA carcinoembryonic antigen
CEACAM5 carcinoembryonic antigen cell adhesion molecule 5
Pgp p-glycoprotein
TGF-β transforming growth factor beta
A2cDb A2 cys-diabody
PSCA prostate stem cell antigen

References
1. James, M.L.; Gambhir, S.S. A molecular imaging primer: Modalities, imaging agents, and applications. *Physiol. Rev.* 2012, 92, 897–965. [CrossRef] [PubMed]
2. Vaz, S.C.; Oliveira, F.; Herrmann, K.; Veit-Haibach, P. Nuclear medicine and molecular imaging advances in the 21st century. *Br. J. Radiol.* 2020, 93, 20200095. [CrossRef] [PubMed]
3. Ikoma, N. ASO Author Reflections: Fluorescent-Image Guidance in Surgical Oncology. *Ann. Surg. Oncol.* 2020, 27, 5323–5324. [CrossRef]

4. Hernandez Vargas, S.; Lin, C.; Tran Cao, H.S.; Ikoma, N.; AghaAmiri, S.; Ghosh, S.C.; Uselmann, A.J.; Azhdarinia, A. Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents. *Front. Oncol.* 2021, 11, 674083. [CrossRef]

5. van Dam, O.M.; Themelis, G.; Crane, L.M.; Harlaar, N.J.; Pleijhuis, R.G.; Kelder, W.; Sarantopoulos, A.; de Jong, J.S.; Arts, H.J.; van der Zee, A.G.; et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: First-in-human results. *Nat. Med.* 2011, 17, 1315–1319. [CrossRef][PubMed]

6. Tummers, Q.R.; Hoogstins, C.E.; Gaarenstroom, K.N.; de Kroon, C.D.; van Poelgeest, M.I.; Vuyk, J.; Bosse, T.; Smit, V.T.; van de Velde, C.J.; Cohen, A.E.; et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. *Oncoarget* 2016, 7, 32144–32155. [CrossRef]

7. Patil, C.G.; Walker, D.G.; Miller, D.M.; Butte, P.; Morrison, B.; Kittle, D.S.; Hansen, S.J.; Nufer, K.L.; Byrness-Blake, K.A.; Yamada, M.; et al. Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas. *Neurosurgery* 2019, 85, E641–E649. [CrossRef]

8. Harlaar, N.J.; Kelder, W.; Sarantopoulos, A.; Bart, J.; Themelis, G.; van Dam, G.M.; Ntziaichristos, V. Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an alpha(v)beta(3)-integrin targeted agent. *Gynecol. Oncol.* 2013, 128, 590–595. [CrossRef]

9. Hoogstins, C.E.; Tummers, Q.R.; Gaarenstroom, K.N.; de Kroon, C.D.; Trimbos, J.B.; Bosse, T.; Smit, V.T.; Vuyk, J.; van de Velde, C.J.; Cohen, A.E.; et al. A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer. *Clin. Cancer Res.* 2016, 22, 2929–2938. [CrossRef]

10. Crane, L.M.; van Oosten, M.; Pleijhuis, R.G.; Motekallemi, A.; Dowdy, S.C.; Cliby, W.A.; van der Zee, A.G.; van Dam, G.M. Intraoperative imaging in ovarian cancer: Fact or fiction? *Mol. Imaging Biol.* 2011, 10, 248–257. [CrossRef]

11. Garland, M.; Yim, J.J.; Bogyo, M. A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application. *Cell Chem. Biol.* 2016, 23, 122–136. [CrossRef][PubMed]

12. Zhang, R.R.; Schroeder, A.B.; Grudzinski, J.J.; Rosenthal, E.L.; Warram, J.M.; Pinchuk, A.N.; Eliceiri, K.W.; Kuo, J.S.; Weichert, J.P. Beyond the margins: Real-time detection of cancer using targeted fluorophores. *Nat. Rev. Clin. Oncol.* 2017, 14, 347–364. [CrossRef][PubMed]

13. Azhdarinia, A.; Ghosh, P.; Ghosh, S.; Wilganowski, N.; Sevick-Muraca, E.M. Dual-labeling strategies for nuclear and fluorescence molecular imaging: A review and analysis. *Mol. Imaging Biol.* 2012, 14, 261–276. [CrossRef][PubMed]

14. Houston, J.P.; Ke, S.; Wang, W.; Li, C.; Sevick-Muraca, E.M. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. *J. Biomed. Opt.* 2005, 10, 054010. [CrossRef][PubMed]

15. Garanger, E.; Aikawa, E.; Reynolds, F.; Weissleder, R.; Josephson, L. Simplified syntheses of complex multifunctional nanomaterials. *Chem. Commun.* 2008, 4792–4794. [CrossRef]

16. Xu, H.; Baidoo, K.; Gunn, A.J.; Boswell, C.A.; Milenic, D.E.; Choyke, P.L.; Brechbiel, M.W. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. *J. Med. Chem.* 2007, 50, 4759–4765. [CrossRef]

17. Liu, S.; Li, D.; Huang, C.W.; Yap, L.P.; Park, R.; Shan, H.; Li, Z.; Conti, P.S. Efficient construction of PET/fluorescence probe based on sarcophagine cage: An opportunity to integrate diagnosis with treatment. *Mol. Imaging Biol.* 2012, 14, 718–724. [CrossRef][PubMed]

18. Hernandez Vargas, S.; Ghosh, S.C.; Azhdarinia, A. New Developments in Dual-Labeled Molecular Imaging Agents. *J. Nucl. Med.* 2019, 60, 459–465. [CrossRef]

19. Hekman, M.C.; Rijpkema, M.; Muselaers, C.H.; Oosterwijk, E.; Hulsbergen-Van de Kaa, C.A.; Boerman, O.C.; Oyen, W.J.; Langenhuijsen, J.F.; Mulders, P.F. Targeted dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. *Theranostics* 2018, 8, 2161–2170. [CrossRef]

20. Li, D.; Zhang, J.; Chi, C.; Xiao, X.; Wang, J.; Lang, L.; Ali, I.; Niu, G.; Zhang, L.; Tian, J.; et al. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using (68)Ga-IRDye800CW-BBN. *Theranostics* 2018, 8, 2508–2520. [CrossRef]

21. Mahalingam, S.M.; Kularatne, S.A.; Myers, C.H.; Gagare, P.; Norshi, M.; Liu, X.; Singhal, S.; Low, P.S. Evaluation of Novel Tumor-Targeted Near-Infrared Probe for Fluorescence-Guided Surgery of Cancer. *J. Med. Chem.* 2018, 61, 9637–9646. [CrossRef][PubMed]

22. van Leeuwen, F.W.B.; Schottelius, M.; Brouwer, O.R.; Vidal-Sicart, S.; Achilefu, S.; Klode, J.; Wester, H.J.; Buckle, T. Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance. *J. Nucl. Med.* 2020, 61, 13–19. [CrossRef][PubMed]

23. Aritzia, J.; Solmont, K.; Moise, N.P.; Specklin, S.; Heck, M.P.; Lamande-Langle, S.; Kuhnast, B. PET/Fluorescence Imaging: An Overview of the Chemical Strategies to Build Dual Imaging Tools. *Bioconjug Chem.* 2022, 33, 24–52. [CrossRef][PubMed]

24. Ni, D.; Ehlerding, E.B.; Cai, W. Multimodality Imaging Agents with PET as the Fundamental Pillar. *Theranostics* 2018, 8, 2570–2579. [CrossRef][PubMed]

25. Seibold, U.; Wangel, B.; Schirrmacher, R.; Wangel, C. Bimodal imaging probes for combined PET and OE: Recent developments and future directions for hybrid agent development. *Biomed. Res. Int.* 2014, 2014, 153741. [CrossRef]

26. Singh, G.; Gott, M.D.; Pietzsch, H.J.; Stephan, H. Nuclear and optical dual-labelled imaging agents. Design and challenges. *Nuklearmedizin* 2016, 55, 41–50. [CrossRef]
27. Yi, X.; Wang, F.; Qin, W.; Yang, Y.; Yuan, J. Near-infrared fluorescent probes in cancer imaging and therapy: An emerging field. *Int. J. Nanomed.* 2014, 9, 1347–1365. [CrossRef]

28. Debie, P.; Hemot, S. Emerging Fluorescent Molecular Tracers to Guide Intra-Operative Surgical Decision-Making. *Front. Pharmacol.* 2019, 10, 510. [CrossRef]

29. Ahn, S.H.; Boros, E. Nuclear and Optical Bimodal Imaging Probes Using Sequential Assembly: A Perspective. *Cancer Biother. Radiopharm.* 2018, 33, 308–315. [CrossRef]

30. Patterson, D.M.; Nazarova, I.A.; Prescher, J.A. Finding the right (bioorthogonal) chemistry. *ACS Chem. Biol.* 2014, 9, 592–605. [CrossRef]

31. Scinto, S.L.; Bilodeau, D.A.; Hincapie, R.; Lee, W.; Nguyen, S.S.; Xu, M.; Am Ende, C.W.; Finn, M.G.; Lang, K.; Lin, Q.; et al. Bioorthogonal chemistry. *Nat. Rev. Methods Primers* 2021, 1, 30. [CrossRef]

32. Sletten, E.M.; Bertozzi, C.R. Bioorthogonal chemistry: Fishing for selectivity in a sea of functionality. *Angew. Chem.* 2009, 48, 6974–6998. [CrossRef]

33. Wang, Y.; Weng, J.; Lin, J.; Ye, D.; Zhang, Y. NIR Scaffold Bearing Three Handles for Biocompatible Sequential Click Installation of Multiple Functional Arms. *J. Am. Chem. Soc.* 2020, 142, 2787–2794. [CrossRef]

34. Perrin, D.M. [(18)F]-Organotrifluoroborates as Radioprosthetic Groups for PET Imaging: From Design Principles to Preclinical Applications. *Acc. Chem. Res.* 2016, 49, 1334–1343. [CrossRef]

35. Kommidi, H.; Guo, H.; Nurilli, F.; Vedvyas, Y.; Jin, M.M.; McClure, T.D.; Ehdaie, B.; Sayman, H.B.; Akin, O.; Aras, O.; et al. A Fluorescent, [(18)F]-Positron Emitting/Mitomycin Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management. *J. Med. Chem.* 2018, 61, 4256–4262. [CrossRef]

36. Guo, H.; Kommidi, H.; Vedvyas, Y.; McCloskey, J.E.; Zhang, W.; Chen, N.; Nurilli, F.; Wu, A.P.; Sayman, H.B.; Akin, O.; et al. A Fluorescent, [(18)F]-Positron Emitter for Imaging Prostate-Specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells. *ACS Chem. Biol.* 2019, 14, 1449–1459. [CrossRef]

37. Aras, O.; Demirdag, C.; Kommidi, H.; Guo, H.; Pavlova, I.; Aygun, A.; Karayel, E.; Pehlivanoglu, H.; Yeyin, N.; Kyprianou, N.; et al. A Small Molecule, Multimodal, [(18)F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study. *Clin. Genitourin. Cancer* 2021, 19, 405–416. [CrossRef]

38. Ghosh, S.C.; Rodriguez, M.; Carmon, K.S.; Voss, J.; Wilganowski, N.L.; Schonbrunn, A.; Azhdarinia, A. A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting. *J. Nucl. Med.* 2017, 58, 1858–1864. [CrossRef]

39. Hernandez Vargas, S.; Kossatz, S.; Voss, J.; Ghosh, S.C.; Tran Cao, H.S.; Simien, J.; Reiner, T.; Dhingra, S.; Fisher, W.E.; Azhdarinia, A. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. *Clin. Cancer Res.* 2019, 25, 4332–4342. [CrossRef]

40. Ghosh, S.C.; Hernandez Vargas, S.; Rodriguez, M.; Kossatz, S.; Voss, J.; Carmon, K.S.; Reiner, T.; Schonbrunn, A.; Azhdarinia, A. Synthesis of a Fluorescently Labeled (68)Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. *ACS Med. Chem. Lett.* 2017, 8, 720–725. [CrossRef]

41. Lutje, S.; Rijpkema, M.; Goldenberg, D.M.; van Rij, C.M.; Sharkey, R.M.; McBride, W.J.; Franssen, G.M.; Frietlink, C.; Helfrich, W.; Oyen, W.J.; et al. Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer. *Cancer Res.* 2014, 74, 6216–6223. [CrossRef]

42. Sibinga Mulder, B.G.; Handgraaf, H.J.; Vugts, D.J.; Sewing, C.; Windhorst, A.D.; Stamnes, M.; de Geus-Oei, L.F.; Bordo, M.W.; Meeog, J.S.D.; van de Velde, C.J.; et al. A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer. *Am. J. Nucl. Med. Mol. Imaging* 2018, 8, 282–291. [CrossRef]

43. Houghton, J.L.; Zeglis, B.M.; Abdel-Atti, D.; Aggeler, R.; Sawada, R.; Agnew, B.J.; Scholz, W.W.; Lewis, J.S. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, and multimodal PET/NIRF imaging of pancreatic cancer. *Proc. Natl. Acad. Sci. USA* 2015, 112, 15850–15855. [CrossRef]

44. Adumeau, P.; Carnazza, K.E.; Brand, C.; Carlin, S.D.; Reiner, T.; Agnew, B.J.; Lewis, J.S.; Zeglis, B.M. A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. *Theranostics* 2016, 6, 2267–2277. [CrossRef]

45. Adumeau, P.; Raavé, R.; Boswinkel, M.; Heskamp, S.; Wessels, H.J.C.T.; van Goor, A.J.; Moreau, M.; Bernhard, C.; Da Costa, L.; Goncalves, V.; et al. Site-Specific, Platform-Based Conjugation Strategy for the Synthesis of Dual-Labeled Immunonoconjugates for Multimodal PET/NIRF Imaging of HER2-Positive Tumors. *Bioconjugate Chem.* 2022, 33, 530–540. [CrossRef]

46. Buckle, T.; van Willigen, D.M.; Spa, S.J.; Hensbergen, A.W.; van der Wal, S.; de Korne, C.M.; Welling, M.M.; van der Poel, H.G.; Hardwick, J.C.H.; van Leeuwen, F.W.B. Tracers for Fluorescence-Guided Surgery: How Elongation of the Polyethylene Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality [rGd-DY] Tracer. *J. Nucl. Med.* 2018, 59, 986–992. [CrossRef]

47. Summer, D.; Petrik, M.; Mayr, S.; Hermann, M.; Kaeopookum, P.; Pfister, J.; Klingler, M.; Rangger, C.; Haas, H.; Decristoforo, C. Hybrid Imaging Agents for Pretargeting Applications Based on Fusaroline C-Proof of Concept. *Molecules* 2020, 25, 2123. [CrossRef]

48. Xia, Y.; Zhang, L.; Zhao, Y.; Liu, X.; Cai, L.; Liu, L.; Chen, Y.; Zhang, W. Gallium-68-Labelled Indocyanine Green as a Potential Liver Reserve Imaging Agent. *Contrast Media Mol. Imaging* 2019, 2019, 420335. [CrossRef]

49. Wu, J.; Pan, D.; Chung, L.W. Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer. *Transl. Androl. Urol.* 2013, 2, 254–264. [CrossRef]
50. Zhang, C.; Zhao, Y.; Zhao, N.; Tan, D.; Zhang, H.; Chen, X.; Zhang, H.; An, J.; Shi, C.; Li, M. NIRF Optical/PET Dual-Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye. *Contrast Media Mol. Imaging* **2018**, *2018*, 4979746. [CrossRef]

51. Shi, C.; Wu, J.B.; Chu, G.C.; Li, Q.; Wang, R.; Zhang, C.; Zhang, Y.; Kim, H.L.; Wang, J.; Zhu, H.E.; et al. Heptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1alpha/OATPs signaling axis. *Oncotarget* **2014**, *5*, 10114–10126. [CrossRef]

52. Zhang, Y.; Xiao, L.; Popovic, K.; Xie, X.; Chordia, M.D.; Chung, L.W.; Williams, M.B.; Yue, W.; Pan, D. Novel cancer-targeting SPECT/NIRF dual-modality imaging probe (99m)Tc-PC-1007. Synthesis and biological evaluation. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 6350–6354. [CrossRef]

53. Xiao, L.; Zhang, Y.; Yue, W.; Xie, X.; Wang, J.P.; Chordia, M.D.; Chung, L.W.; Pan, D. Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: Synthesis and in vivo evaluation. *Nucl. Med. Biol.* **2013**, *40*, 351–360. [CrossRef]

54. Baranski, A.C.; Schafer, M.; Bauder-Wust, U.; Roscher, M.; Schmidt, J.; Stenau, E.; Simpfenдорfer, T.; Teber, D.; Maier-Hein, L.; Hadaschik, B.; et al. PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. *J. Nucl. Med.* **2018**, *59*, 639–645. [CrossRef]

55. Sun, Y.; Zeng, X.; Yao, Y.; Liu, C.; Zhu, H.; Zhou, H.; Chen, Z.; Xue, F.; Wang, J.; Zhu, M.; et al. Novel dual-function near-infrared II fluorescence and PET probe for tumor delineation and image-guided surgery. *Chem. Sci.* **2018**, *9*, 2092–2097. [CrossRef]

56. Summer, D.; Grossrubatscher, L.; Petrik, M.; Michalcikova, T.; Novy, Z.; Rangger, C.; Klingler, M.; Haas, H.; Kaeopookum, P.; von Guggenberg, E.; et al. Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding. *Bioconjug Chem.* **2017**, *28*, 1722–1733. [CrossRef]

57. Derks, Y.H.W.; Rijpkema, M.; Amatdjais-Groenen, H.I.V.; Loeff, C.C.; de Roode, K.E.; Kip, A.; LaVermer, P.; Lutjens, S.; Heskamp, S.; Lomdik, D. Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer. *Bioconjug Chem.* **2022**, *33*, 194–205. [CrossRef]

58. Boonstra, M.C.; van Driel, P.B.; van Willigen, D.M.; Stammes, M.A.; Prevoo, H.A.; Tummers, Q.R.; Mazar, A.P.; Beekman, F.J.; Kuppen, P.J.; van de Velde, C.J.; et al. uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery. *Oncotarget* **2015**, *6*, 14260–14273. [CrossRef]

59. Boonstra, M.C.; Van Driel, P.; Keereweere, S.; Prevoo, H.; Stammes, M.A.; Baart, V.M.; Lowik, D.; Mazar, A.P.; van de Velde, C.J.H.; Vahrmeijer, A.L.; et al. Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer. *Oral. Oncol.* **2017**, *66*, 1–8. [CrossRef]

60. Hekman, M.C.H.; Boerman, O.C.; Bos, D.L.; Massuger, L.; Weil, S.; Grasso, L.; Rybinski, K.A.; Oosterwijk, E.; Mulders, P.F.A.; Rijpkema, M. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging. *Mol. Pharm.* **2017**, *14*, 3457–3463. [CrossRef]

61. Hall, M.A.; Kwon, S.; Robinson, H.; Lachance, P.A.; Azhdarinia, A.; Ranganathan, R.; Price, R.E.; Chan, W.; Sevick-Muraca, E.M. Imaging prostate cancer lymph node metastases with a multimodality contrast agent. *Prostate* **2012**, *72*, 129–146. [CrossRef] [PubMed]

62. Odenthal, J.; Rijpkema, M.; Bos, D.; Wagena, E.; Croles, H.; Grenman, R.; Boerman, O.; Takes, R.; Friedl, P. Targeting CD105 expression using a dual-labeled monoclonal antibody for fluorescence-guided surgery in head and neck squamous cell carcinoma. *Sci. Rep.* **2018**, *8*, 10467. [CrossRef] [PubMed]

63. Hong, H.; Zhang, Y.; Severin, G.W.; Yang, Y.; Engle, J.W.; Niu, G.; Nickles, R.J.; Chen, X.; Leigh, B.R.; Barnhart, T.E.; et al. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. *Mol. Pharm.* **2012**, *9*, 2339–2349. [CrossRef] [PubMed]

64. Zhang, Y.; Hong, H.; Yang, Y.; Theuer, C.P.; Barnhart, T.E.; Cai, W. Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. *Angiogenesis* **2013**, *16*, 663–674. [CrossRef]

65. Zhang, Y.; Hong, H.; Engle, J.W.; Yang, Y.; Theuer, C.P.; Barnhart, T.E.; Cai, W. Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. *Mol. Pharm.* **2012**, *9*, 645–653. [CrossRef]

66. Zhang, Y.; Hong, H.; Severin, G.W.; Engle, J.W.; Yang, Y.; Goel, S.; Nathanson, A.J.; Liu, G.; Nickles, R.J.; Leigh, B.R.; Barnhart, T.E.; et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. *Am. J. Transl. Res.* **2012**, *4*, 333–346. [PubMed]

67. Lee, H.J.; Ehlerding, E.B.; Jiang, D.; Barnhart, T.E.; Cao, T.; Wei, W.; Ferreira, C.A.; Huang, P.; Engle, J.W.; Cai, W. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. *Am. J. Cancer Res.* **2019**, *9*, 1454–1468. [PubMed]

68. Oliveira, S.; Cohen, R.; Walsum, M.S.; van Dongen, G.A.; Elias, S.G.; van Diest, P.J.; Mali, W.; van Bergen En Henegouwen, P.M. A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. *EJNMMI Res.* **2012**, *2*, 50. [CrossRef]

69. Hernandez, R.; Sun, H.; England, C.G.; Valdivinos, H.F.; Ehlerding, E.B.; Barnhart, T.E.; Yang, Y.; Cai, W. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. *Theranostics* **2016**, *6*, 1918–1933. [CrossRef]

70. Zhang, Y.; Hong, H.; Engle, J.W.; Yang, Y.; Barnhart, T.E.; Cai, W. Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. *Am. J. Nucl. Med. Mol. Imaging* **2012**, *2*, 1–13.
Cancers 2022, 14, 1619

71. Muselaers, C.H.; Rijpkema, M.; Bos, D.L.; Langenhuijzen, J.F.; Oyen, W.J.; Mulders, P.F.; Oosterwijk, E.; Boerman, O.C. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. J. Urol. 2015, 194, 532–538. [CrossRef] [PubMed]

72. Hekman, M.C.; Boerman, O.C.; de Weijert, M.; Bos, D.L.; Oosterwijk, E.; Langenhuijzen, J.F.; Mulders, P.F.; Rijpkema, M. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study. Clin. Cancer Res. 2016, 22, 4634–4642. [CrossRef] [PubMed]

73. Hekman, M.C.H.; Rijpkema, M.; Bos, D.L.; Oosterwijk, E.; Goldenberg, D.M.; Mulders, P.F.A.; Boerman, O.C. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. J. Nucl. Med. 2017, 58, 706–710. [CrossRef]

74. Lutje, S.; Rijpkema, M.; Franssen, G.M.; Fracasso, G.; Helfrich, W.; Eek, A.; Oyen, W.J.; Colombatti, M.; Boerman, O.C. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody. J. Nucl. Med. 2015, 55, 995–1001. [CrossRef] [PubMed]

75. Rijpkema, M.; Oyen, W.J.; Bos, D.; Franssen, G.M.; Goldenberg, D.M.; Boerman, O.C. SPECT- and fluorescence image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody. J. Nucl. Med. 2014, 55, 1519–1524. [CrossRef]

76. Rijpkema, M.; Bos, D.L.; Corneliussen, A.S.; Franssen, G.M.; Goldenberg, D.M.; Oyen, W.J.; Boerman, O.C. Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. Mol. Imaging 2015, 14, 348–355. [CrossRef]

77. Wang, M.; Mao, C.; Wang, H.; Ling, X.; Wu, Z.; Li, Z.; Ming, X. Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe. Mol. Pharm. 2017, 14, 3391–3398. [CrossRef]

78. Luo, H.; England, C.G.; Goel, S.; Graves, S.A.; Ai, F.; Liu, B.; Theuer, C.P.; Wong, H.C.; Nickles, R.J.; Cai, W. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. Mol. Pharm. 2017, 14, 1646–1655. [CrossRef]

79. Zhang, X.; Ding, B.; Qu, C.; Li, H.; Sun, Y.; Gai, Y.; Chen, H.; Fang, H.; Qian, K.; Zhang, Y.; et al. A thiopyrylum salt for PET/NIR-II tumor imaging and image-guided surgery. Mol. Oncol. 2020, 14, 1089–1100. [CrossRef]

80. Zettlitz, K.A.; Tsai, W.K.; Knowles, S.M.; Kobayashi, N.; Donahue, T.R.; Reiter, R.E.; Wu, A.M. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. J. Nucl. Med. 2018, 59, 1398–1405. [CrossRef]

81. Privat, M.; Bellaye, P.S.; Lescura, R.; Massot, A.; Baffroy, O.; Moreau, C.; Marcion, G.; Denat, F.; Bettaieb, A.; et al. Development of an Easily Bioconjugatable Water-Soluble Single-Photon Emission-Computed Tomography/Optical Imaging Bimodal Imaging Probe Based on the aza-BODIPY Fluorophore. J. Med. Chem. 2021, 64, 11063–11073. [CrossRef] [PubMed]

82. Peltek, O.O.; Muslimov, A.R.; Zyuzin, M.V.; Timin, A.S. Current outlook on radionuclide delivery systems: From design consideration to translation into clinics. J. Nanobiotechnol. 2019, 17, 90. [CrossRef] [PubMed]

83. Herrero Alvarez, N.; Bauer, D.; Hernandez-Gil, J.; Lewis, J.S. Recent Advances in Radiometals for Combined Imaging and Therapy. ChemMedChem 2021, 16, 2909–2941. [CrossRef] [PubMed]

84. Price, E.W.; Orvig, C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2014, 43, 260–290. [CrossRef]

85. Feng, Z.; Tang, T.; Wu, T.; Yu, X.; Zhang, Y.; Wang, M.; Zheng, J.; Ying, Y.; Chen, S.; Zhou, J.; et al. Perfecting and extending the near-infrared imaging window. Light Sci. Appl. 2021, 10, 197. [CrossRef]

86. Hong, G.; Antaris, A.L.; Dai, H. Near-infrared fluorophores for biomedical imaging. Nat. Biomed. Eng. 2017, 1, 0010. [CrossRef]

87. Frangioni, J.V. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 2003, 7, 626–634. [CrossRef]

88. Lim, Y.T.; Kim, S.; Nakayama, A.; Stott, N.E.; Bawendi, M.G.; Frangioni, J.V. Selection of Quantum Dot Wavelengths for Biomedical Assays and Imaging. Mol. Imaging 2003, 2, 50–64. [CrossRef]

89. He, S.; Song, J.; Qu, J.; Cheng, Z. Crucial breakthrough of second near-infrared biological window fluorophores: Design and synthesis toward multimodal imaging and theranostics. Chem. Soc. Rev. 2018, 47, 4258–4278. [CrossRef]

90. Ntziachristos, V.; Bremer, C.; Weissleder, R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur. Radiol. 2003, 13, 195–208. [CrossRef]

91. Strangman, G.; Boas, D.A.; Sutton, J.P. Non-invasive neuroimaging using near-infrared light. Biol. Psychiatry 2002, 52, 679–693. [CrossRef]
121. Li, D.H.; Schreiber, C.L.; Smith, B.D. Sterically Shielded Heptamethine Cyanine Dyes for Bioconjugation and High Performance Near-Infrared Fluorescence Imaging. *Angew. Chem.* 2020, 59, 12154–12161. [CrossRef] [PubMed]

122. Yang, X.; Shi, C.; Tong, R.; Qian, W.; Zhou, H.E.; Wang, R.; Zhu, G.; Cheng, J.; Yang, W.V.; Cheng, T.; et al. Near IR heptamethine cyanine dye-mediated cancer imaging. *Clin. Cancer Res.* 2010, 16, 2833–2844. [CrossRef] [PubMed]

123. Luo, S.; Zhang, E.; Su, Y.; Cheng, T.; Shi, C. A review of NIR dyes in cancer targeting and imaging. *Biomaterials* 2011, 32, 7127–7138. [CrossRef] [PubMed]

124. Shi, C.; Wu, J.B.; Fan, D. Review on near-infrared heptamethine cyanine dyes as theranostic agents for tumor imaging, targeting, and photodynamic therapy. *J. Biomed. Opt.* 2016, 21, 50901. [CrossRef] [PubMed]

125. Usama, S.M.; Burgess, K. Hows and Whys of Tumor-Seeking Dyes. *ACS Chem. Biol.* 2022, 9, 2121–2131. [CrossRef] [PubMed]

126. Usama, S.M.; Liu, C.M.; Burgess, K. On the Mechanisms of Uptake of Tumor-Seeking Cyanine Dyes. *Bioconjug Chem.* 2018, 29, 3886–3895. [CrossRef] [PubMed]

127. Usama, S.M.; Park, G.K.; Nomura, S.; Baek, Y.; Choi, H.S.; Burgess, K. Role of Albumin in Accumulation and Persistence of Tumor-Seeking Cyanine Dyes. *Bioconjug Chem.* 2020, 31, 248–259. [CrossRef]

128. Wu, J.B.; Shi, C.; Chu, G.C.; Xu, Q.; Zhang, Y.; Li, Q.; Yu, J.S.; Zhou, H.E.; Chung, L.W. Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor. *Biomaterials* 2015, 67, 1–10. [CrossRef] [PubMed]

129. Thavornpradit, S.; Usama, S.M.; Park, G.K.; Shrestha, J.P.; Nomura, S.; Baek, Y.; Choi, H.S.; Burgess, K. QuatCy: A Heptamethine Cyanine Modification With Improved Characteristics. *Theranostics* 2019, 9, 2856–2867. [CrossRef]

130. Friedman, H.C.; Cosco, E.D.; Atallah, T.L.; Jia, S.; Sletten, E.M.; Caram, J.R. Establishing design principles for emissive organic SWIR chromophores from energy gap laws. *Chem. 2021, 7, 3359–3376. [CrossRef]*

131. Egbuna, C.; Parmar, V.K.; Jeevanandam, J.; Ezzat, S.M.; Patrick-Iwuanyanwu, K.C.; Adetunji, C.O.; Khan, J.; Onyeike, E.N.; Uche, C.Z.; Akram, M.; et al. Toxicity of Nanoparticles in Biomedical Application: Nanotoxicology. *J. Toxicol.* 2021, 2021, 995443. [CrossRef] [PubMed]

132. Longmire, M.; Choyke, P.L.; Kobayashi, H. Clearances properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. *Nanomedicine* 2008, 3, 703–717. [CrossRef] [PubMed]

133. Dai, H.; Shen, Q.; Shao, J.; Wang, W.; Gao, F.; Dong, X. Small Molecular NIR-II Fluorophores for Cancer Photothnanostics. *Innovation* 2021, 2, 100082. [CrossRef] [PubMed]

134. Haute, D.V.; Berlin, J.M. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: Lessons from gold nanoparticles. *Ther. Deliv.* 2017, 8, 763–774. [CrossRef]

135. Ono, K.; Tanaka, S.; Yamashita, Y. Benzobis(Thiadiazole)S Containing Hypervalent Sulfur-Atoms—Novel Heterocycles with High NIR-II imaging. *Nat. Chem.* 2020, 12, 1123–1130. [CrossRef] [PubMed]

136. Antaris, A.L.; Chen, H.; Cheng, K.; Sun, Y.; Hong, G.; Qu, C.; Diao, S.; Deng, Z.; Hu, X.; Zhang, B.; et al. A small-molecule dye for NIR-II imaging. *Nat. Mater.* 2016, 15, 235–242. [CrossRef]

137. Wan, H.; Ma, H.; Zhu, S.; Wang, F.; Tian, Y.; Ma, R.; Yang, Q.; Hu, Z.; Zhu, T.; Wang, W.; et al. Developing a Bright NIR-II Fluorophore with Fast Renal Excretion and Its Application in Molecular Imaging Platform PD-L1. *Adv. Funct. Mater.* 2018, 28. [CrossRef]

138. Carr, J.A.; Franke, D.; Caram, J.R.; Perkinson, C.F.; Saif, M.; Askoxylakis, V.; Datta, M.; Fukumura, D.; Jain, R.K.; Bawendi, M.G.; et al. Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green. *Proc. Natl. Acad. Sci. USA* 2018, 115, 4465–4470. [CrossRef]

139. Cosco, E.D.; Spearman, A.L.; Ramakrishnan, S.; Lingg, J.G.P.; Saccomano, M.; Pengshung, M.; Arus, B.A.; Wong, K.C.Y.; Glasl, S.; Ntzchiarchis, V.; et al. Shortwave infrared polymethine fluorophores matched to excitation lasers enable non-invasive, multicolour in vivo imaging in real time. *Nat. Chem.* 2020, 12, 1123–1130. [CrossRef]

140. Cosco, E.D.; Caram, J.R.; Bruns, O.T.; Franke, D.; Day, R.A.; Farr, E.P.; Bawendi, M.G.; Sletten, E.M. Flavilyum Polymethine Fluorophores for Near- and Shortwave Infrared Imaging. *Angew. Chem.* 2017, 56, 13126–13129. [CrossRef]

141. Cosco, E.D.; Arus, B.A.; Spearman, A.L.; Atallah, T.L.; Lim, I.; Leland, O.S.; Caram, J.R.; Bischof, T.S.; Bruns, O.T.; Sletten, E.M. Bright Chromenilyium Polymethine Dyes Enable Fast, Four-Color In Vivo Imaging with Shortwave Infrared Detection. *J. Am. Chem. Soc.* 2021, 143, 6836–6846. [CrossRef]

142. Bandi, V.G.; Luciano, M.P.; Saccomano, M.; Patel, N.P.; Bischof, T.P.; Lingg, J.G.P.; Tsuruken, P.T.; Nix, M.N.; Ruehle, B.; Sanders, C.; et al. Targeted Multicolor In Vivo Imaging Over 1000 nm Enabled by Nonamethylene Cyanines. *Nat. Methods* 2022, 19, 353–358. [CrossRef]

143. Costa, I.M.; Cheng, J.; Ozytek, K.M.; Imberti, C.; Terry, S.Y.A. Methods and techniques for in vitro subcellular localization of radiopharmaceuticals and radionuclides. *Nucl. Med. Biol.* 2021, 98–99, 18–29. [CrossRef]

144. Elekonawo, F.M.K.; de Gooyer, J.M.; Bos, D.L.; Goldenberg, D.M.; Boerman, O.C.; Brosens, L.A.A.; Bremers, A.J.A.; de Wilt, J.H.W.; Rijpkema, M. Ex Vivo Assessment of Tumor-Targeting Fluorescent Tracers for Image-Guided Surgery. *Cancers* 2020, 12, 987. [CrossRef]

145. Drago, J.Z.; Modi, S.; Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. *Nat. Rev. Clin. Oncol.* 2021, 18, 327–344. [CrossRef]

146. Chyan, W.; Raines, R.T. Enzyme-Activated Fluorogenic Probes for Live-Cell and In Vivo Imaging. *ACS Chem. Biol.* 2018, 13, 1810–1823. [CrossRef]
147. Bruemmer, K.J.; Crossley, S.W.M.; Chang, C.J. Activity-Based Sensing: A Synthetic Methods Approach for Selective Molecular Imaging and Beyond. Angew. Chem. Int. Ed. Engl. 2020, 59, 13734–13762. [CrossRef]

148. Li, H.; Kim, D.; Yao, Q.; Ge, H.; Chung, J.; Fan, J.; Wang, J.; Peng, X.; Yoon, J. Activity-Based NIR Enzyme Fluorescent Probes for the Diagnosis of Tumors and Image-Guided Surgery. Angew. Chem. Int. Ed. Engl. 2021, 60, 17268–17289. [CrossRef]

149. Kasten, B.B.; Jiang, K.; Cole, D.; Jani, A.; Udayakumar, N.; Gillespie, G.Y.; Lu, G.; Dai, T.; Rosenthal, E.L.; Markert, J.M.; et al. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1412–1426. [CrossRef]

150. Usama, S.M.; Inagaki, F.; Kobayashi, H.; Schnerrmann, M.J. Norcyanine-Carbamates Are Versatile Near-Infrared Fluorogenic Probes. J. Am. Chem. Soc. 2021, 143, 5674–5679. [CrossRef]

151. Usama, S.M.; Marker, S.C.; Caldwell, D.R.; Patel, N.L.; Feng, Y.; Kalen, J.D.; St Croix, B.; Schnerrmann, M.J. Targeted Fluorogenic Cyanine Carbamates Enable In Vivo Analysis of Antibody-Drug Conjugate Linker Chemistry. J. Am. Chem. Soc. 2021, 143, 21667–21675. [CrossRef]

152. Pham, T.C.; Nguyen, V.N.; Choi, Y.; Lee, S.; Yoon, J. Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. Chem. Rev. 2021, 121, 13454–13619. [CrossRef]

153. Li, X.; Lovell, J.F.; Yoon, J.; Chen, X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol. 2020, 17, 657–674. [CrossRef]

154. Usama, S.M.; Thavornpradit, S.; Burgess, K. Optimized Heptamethine Cyanines for Photodynamic Therapy. ACS Appl. Bio. Mater. 2018, 1, 1195–1205. [CrossRef]

155. Lujić, S.; Heskamp, S.; Franssen, G.M.; Friedink, C.; Kip, A.; Heekman, M.; Herrmann, K.; Boerman, O.C.; et al. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors. Theranostics 2019, 9, 2924–2938. [CrossRef]

156. Renard, E.; Collado Camps, E.; Canovas, C.; Kip, A.; Gotthardt, M.; Rijpkema, M.; Denat, F.; Goncalves, V.; van Lith, S.A.M. Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tumors. Cancers 2021, 13, 428. [CrossRef]

157. Mitsunaga, M.; Ogawa, M.; Kosaka, N.; Rosenblum, L.T.; Choyke, P.L.; Kobayashi, H. Cancer cell-selective in vivo near infrared photoinmunotherapy targeting specific membrane molecules. Nat. Med. 2011, 17, 1685–1691. [CrossRef]

158. Kobayashi, H.; Choyke, P.L. Near-Infrared Photoimmunotherapy of Cancer. Acc. Chem. Res. 2019, 52, 2332–2339. [CrossRef]

159. Derks, Y.H.W.; van Lith, S.A.M.; Amatdjais-Groenen, H.I.V; Wouters, L.W.M.; Kip, A.; Franssen, G.M.; Laverman, P.; Lowik, D.; Heskamp, S.; Rijpkema, M. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2022. [CrossRef]

160. Derks, Y.H.W.; Rijpkema, M.; Amatdjais-Groenen, H.I.V; Kip, A.; Franssen, G.M.; Sedelaar, J.P.M; Somford, D.M.; Simons, M.; Laverman, P.; Gotthardt, M.; et al. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer. Theranostics 2021, 11, 1527–1541. [CrossRef]

161. Cognetti, D.M.; Johnson, J.M.; Curry, J.M.; Kochuparambil, S.T.; McDonald, D.; Mott, F.; Fidler, M.J.; Stenson, K.; Vasan, N.R.; Razaq, M.A.; et al. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck 2021, 43, 3875–3887. [CrossRef]

162. Paraboschi, I.; Turnock, S.; Kramer-Marek, G.; Musleh, L.; Barisa, M.; Anderson, J.; Giuliani, S. Near Infrared Photoimmunotherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. Crit. Rev. Oncol. Hematol. 2021, 161, 103325. [CrossRef]